La sclérose en plaques : aperçu historique, La Lettre du Neurologue, vol.14, issue.2, pp.54-62, 2010. ,
Leçons sur les maladies du système nerveux faites à la Salpêtrière (1872-1873), 2009. ,
Axonal pathology in multiple sclerosis. A historical note, Brain Pathol, vol.9, issue.4, pp.651-657, 1999. ,
Regional variation of multiple sclerosis prevalence in Canada, Mult Scler, vol.11, issue.5, pp.516-525, 2005. ,
An epidemiological study of multiple sclerosis in Cape Town, Southafrica, Advances in Neurology: Proceedings of the 14th World Congress of Neurology, p.278, 1989. ,
Multiple sclerosis in Taiwan, J Chin Med Assoc, vol.67, issue.10, pp.500-505, 2004. ,
, Arsep Fondation Sclérose en plaques
Définition et chiffres, 2016. ,
A reassessment of the distribution of multiple sclerosis. Part one, Acta Neurol Scand, vol.51, issue.2, pp.110-146, 1975. ,
The prevalence of multiple sclerosis in the world: an update, Neurol Sci, vol.22, issue.2, pp.117-156, 2001. ,
Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis, J Neurol Neurosur Ps, vol.82, issue.10, pp.1132-1173, 2011. ,
Enquête sur la sclérose en plaques lancée par la télévision française, Rev Neurol, vol.14, issue.3, pp.135-141, 1988. ,
Regional variations in the prevalence of multiple sclerosis in French farmers, J Neurol Neurosur Ps, vol.8, issue.7, pp.707-716, 2007. ,
Geographic variations of multiple sclerosis in France, Brain, vol.133, issue.7, pp.1889-99, 2010. ,
Epidemiology of multiple sclerosis, Rev Neurol, vol.172, issue.1, pp.3-13, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01255824
Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study Plos One, vol.10, 2015. ,
An excessive risk of suicide may no longer be a reality for multiple sclerosis patients, Mult Scler, vol.23, issue.6, pp.864-71, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01518889
Trends in survival and cause of death in Danish patients with multiple sclerosis, Brain, vol.127, issue.4, pp.844-50, 2004. ,
, Arsep Fondation Sclérose en plaques
Le système nerveux, 2016. ,
Immunité adaptative et physiopathologie de la sclérose en plaques, Rev Med Interne, vol.34, issue.8, pp.479-86, 2013. ,
Immunologie de la sclérose en plaques : évolution des concepts, Rev Neurol, vol.164, issue.2, pp.138-184, 2008. ,
Sclérose en plaques : maladie inflammatoire ou dégénérative ? Neurologie, com, vol.1, issue.4, pp.110-117, 2009. ,
, Académie nationale de médecine
Académie de médecine ,
, La sclérose en plaques : quelles possibilités de régénération ?, 2008.
Disability and T2 MRI lesions : a 20-year follow-up of patients with relapse onset of multiple sclerosis, Brain, vol.131, issue.3, pp.808-825, 2008. ,
La sclérose en plaques en, Images en Ophtalmologie, vol.8, issue.1, pp.10-16, 2014. ,
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis, Neurology, vol.46, issue.4, pp.907-918, 1996. ,
Update on diagnosis and treatment of multiple sclerosis, Rev Med Interne, vol.34, issue.10, pp.628-663, 2013. ,
Anatomopathologie et définition de la sclérose en plaques, Rev Praticien, vol.56, issue.12, pp.1293-98, 2006. ,
La sclérose en plaques, Actualités pharmaceutiques hospitalières, vol.5, pp.14-23, 2009. ,
Defining the clinical course of multiple sclerosis : the 2013 revisions, Neurology, vol.83, issue.3, pp.278-86, 2014. ,
, , 2012.
Neuropsychiatric manifestations of multiple sclerosis, J Neuropsychiatry Clin Neurosci, vol.11, issue.1, pp.51-58, 1999. ,
Cognitive impairment in multiple sclerosis, Lancet Neurol, vol.7, issue.12, pp.1139-51, 2008. ,
Le point sur la sclérose en plaques. Kinésithérapie Rev, vol.12, pp.17-22, 2012. ,
Evaluation clinique du suivi et de l'évolution, Rev Neurol, vol.157, issue.8, pp.1121-1124, 2001. ,
, Arsep Fondation Sclérose en plaques
Les échelles d'évaluation de la SEP, p.106, 2016. ,
Sclérose en plaques, Rev Praticien, vol.59, issue.8, pp.695-701, 2009. ,
Sclérose en plaques : définition et symptomatologie, 2015. ,
,
Bigot-Corbel E. Étude biochimique du liquide céphalorachidien dans le cadre de la sclérose en plaques, Immuno-Anal Biol Spe, vol.18, issue.2, pp.86-95, 2003. ,
Recommended diagnostic criteria for multiple sclerosis : guidelines from the International Panel on the diagnosis of multiple sclerosis, Ann Neurol, vol.50, issue.1, pp.121-128, 2001. ,
Critères diagnostics de la sclérose en plaques, Neurologies, vol.15, issue.144, pp.18-26, 2012. ,
Corticosteroids in the treatment of multiple sclerosis, Acta Neurol Scand, vol.189, issue.2, pp.73-80, 2009. ,
Oral and intravenous steroids for multiple sclerosis relapse : a systematic review and meta-analysis, J Neurol, vol.264, issue.8, pp.1697-704, 2017. ,
Oral versus intravenous high-dose methylprednisolone for treatment of relapses in 107 patients with multiple sclerosis (COPOUSEP) : a randomised, controlled, doubleblind, non-inferiority trial, Lancet, vol.386, issue.9997, pp.974-982, 2015. ,
Multiple sclerosis : current and emerging diseasemodifying therapies and treatment strategies, Mayo Clin Proc, vol.89, issue.2, pp.225-265, 2014. ,
Traitement des formes rémittentes, traitements actuels et à venir, Neurologies, vol.15, issue.148, pp.194-205, 2012. ,
An update of teriflunomide for treatment of multiple sclerosis, Ther Clin Risk Manag, vol.9, issue.2, pp.177-90, 2013. ,
Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: patient preference and adherence, Patient Prefer Adher, vol.9, issue.4, pp.265-74, 2015. ,
BG-12), Forum Med Suisse, vol.13, issue.38, pp.761-762, 2013. ,
,
, Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis, Study Investigators, vol.367, pp.1087-1097, 2012.
Mécanismes immunologiques des traitements de fond de la sclérose en plaques. Pratique neurologique, vol.7, pp.159-65, 2016. ,
The efficacy of natalizumab in patients with relapsing multiple sclerosis : subgroup analyses of AFFIRM and SENTINEL, J Neurol, vol.256, issue.3, pp.405-420, 2009. ,
, ANSM
Natalizumab (Tysabri®) : mise à jour des mesures de réduction du risque de LEMP-Lettre aux professionnels de santé, 2016. ,
CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis : a randomised controlled phase 3 trial, Lancet, vol.380, issue.9856, pp.1819-1847, 2012. ,
Clinical Investigators of the OPERA I and OPERA II. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis, New Engl J Med, vol.376, issue.3, pp.221-255, 2017. ,
De nouveaux atouts contre la SEP ? Actualités pharmaceutiques, vol.50, pp.21-25, 2011. ,
Les immunomodulateurs dans la sclérose en plaques, Neurologie.com, vol.2, issue.3, pp.57-59, 2010. ,
Traitement des formes progressives de sclérose en plaques par cyclophosphamide, Rev Neurol, vol.158, issue.1, pp.65-69, 2002. ,
Biotin Sensing at the Molecular Level, J Nutr, vol.139, issue.1, pp.167-170, 2009. ,
MS-SPI study group. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis : A randomised, doubleblind, placebo-controlled study, Mult Scler, vol.22, issue.13, pp.1719-1750, 2016. ,
, ANSM
Protocole d'utilisation thérapeutique et de recueil d'informations-QIZENDAY 100mg, gélule, 2016. ,
Efficacy and safety of laquinimod in multiple sclerosis : current status, Ther Adv Neurol Disord, vol.6, issue.6, pp.343-52, 2013. ,
, ANSM
Agence nationale de sécurité du médicament et des produits de santé, 2013. ,
Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis, Curr Med Res Opin, vol.27, issue.7, pp.1415-1438, 2011. ,
, World Health Organization [En ligne] Geneva (CH);1948. The First ten years of the World Health Organization
,
The problem of quality of life in medicine, JAMA, vol.278, issue.1, pp.47-50, 1997. ,
, Ministère des Solidarité et de la Santé
Plan 20072011 pour l'amélioration de la qualité de vie des patients atteints de maladies chroniques, 2007. ,
,
La qualité de vie, approches psychologies. PUR, 2014. ,
Guidelines for selecting quality of life assessment : methodological and practical consideration, J Drug Ther Res, vol.13, issue.5, pp.159-163, 1998. ,
Une approche de la qualité de vie : l'évaluation individualisée. Annales de réadaptation et de médecine physique, vol.39, pp.171-177, 1996. ,
Quality of life measurement in children and adolescents : issues, instruments and applications, J Clin Psychol, vol.4, issue.57, pp.571-85, 2001. ,
, World Health Organization. Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL), Qual Life Res, vol.2, issue.2, pp.153-162, 1993.
Recommendations on health-related quality of life research to support labeling and promotional claims in the United States, Qual Life Res, vol.9, issue.8, pp.887-900, 2000. ,
Journées de la Soiété Française de Sénologie et de Pathologie Mammaire, p.111, 2005. ,
Quality of life in health care evaluation and resource allocation, vol.2, pp.478-487, 1993. ,
Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes, JAMA Neurol, vol.273, issue.1, pp.59-65, 1995. ,
Conceptual model of health-related quality of life, J Nurs Scholarship, vol.37, issue.4, pp.336-378, 2005. ,
Mesure de la santé perceptuelle et de la qualité de vie : méthodes et applications, 2002. ,
La qualité de vie et ses mesures, Rev Med Interne, vol.28, issue.7, pp.458-62, 2007. ,
DOI : 10.1016/j.revmed.2007.02.010
, Qaulity of life, 2000.
Evaluation de la ualité de vie chez l'enfant et l'adolescent : qualité de vie et santé. La presse médicale, vol.28, pp.1033-1072, 1999. ,
Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment, CNS Drugs, vol.22, issue.10, pp.827-866, 2008. ,
Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing, Lancet Neurol, vol.4, issue.9, pp.556-66, 2005. ,
The use of patient reported outcome measures in routine clinical practice: lackof impact or lack of theory?, Soc Sci Med, vol.60, issue.4, pp.833-876, 2005. ,
Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials, Neurotherapeutics, vol.14, issue.4, pp.934-978, 2017. ,
Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis, J Neurol Neurosur Ps, vol.76, issue.4, pp.519-545, 2005. ,
La qualité de vie des patients souffrant de sclérose en plaques, Revue Neurologique, vol.165, issue.4, pp.123-131, 2009. ,
Impact of recently diagnosed multiple sclerosis on quality of life, anxiety, depression and distress of patients and partners, Acta Neurol Scand, vol.108, issue.6, pp.389-95, 2003. ,
Quality of life and multiple sclerosis: validation of the french version of the selfquestionnaire (SEP-59), Rev Neurol, vol.156, issue.3, pp.247-63, 2000. ,
Multiple Sclerosis" AND "Quality of life, 2000. ,
,
Quality of life measures for the palliative care of people severely affected by multiple sclerosis : a systematic review, Mult Scler, vol.10, issue.6, pp.690-725, 2004. ,
Measuring the Quality of Life in Patients with Multiple Sclerosis in Clinical Practice: A Necessary Challenge, Mult Scler Int, vol.8, issue.20, pp.1-8, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01096974
Quality of life as a predictor for change in disability in MS, Neurology, vol.55, issue.1, pp.51-55, 2000. ,
Value of health-related quality of life to predict disability course in multiple sclerosis, Neurology, vol.63, issue.11, pp.2046-50, 2004. ,
MusiQoL study group. Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis, Eur J Neurol, vol.20, issue.6, pp.907-921, 2013. ,
Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: assessment using the MusiQoL and SF-36 questionnaires, Mult Scler, vol.17, issue.10, pp.1238-1287, 2011. ,
Les Indicateurs de Qualité de Vie : processus de Mesure et Validation. Cardioscopies, vol.12, pp.635-672, 1995. ,
A health-related quality of life measure for multiplesclerosis, Qual Life Res, vol.4, issue.3, pp.187-206, 1995. ,
Measuring quality of life in multiple sclerosis: not as simple as it sounds, Mult Scler, vol.11, issue.6, pp.708-712, 2005. ,
French validation of the MultIple Sclerosis International Quality of Life Questionnaire, Rev Neurol, vol.167, issue.6-7, pp.511-532, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00617047
,
Validation of the spanish version of the Multiple Sclerosis International Quality of Life (Musiqol) questionnaire, BMC Neurol, vol.11, issue.2, p.127, 2011. ,
MusiQol: international questionnaire investigating quality of life in multiple sclerosis: Validation results for the German subpopulation in an international comparison ,
, Nervenarzt, vol.82, issue.10, pp.1281-1290, 2011.